A Year Into Turnaround, Novo CEO Says Investors Still Underestimate Drug Pipeline
As the GLP-1 market heats up, Novo Nordisk's chief insists Wall Street is missing the full value of its weight-loss and diabetes portfolio.

Loading the region desk
Gathering coverage from this region…
Executive intelligence curated from Americas sources and global coverage.
191 briefings briefings in Americas
As the GLP-1 market heats up, Novo Nordisk's chief insists Wall Street is missing the full value of its weight-loss and diabetes portfolio.
A Florida jury found the plaintiffs failed to prove ownership, ending a damages case that tested the limits of expropriation lawsuits against travel companies.
Investors are betting on a regulatory breakthrough as Tesla edges closer to a robotaxi without manual controls - here's what it means for the EV maker's valuation and the autonomous driving race.
The e-commerce giant fires back at regulators, citing flat ad costs and $230 average consumer savings, as the legal battle over search ad pricing escalates.
The regulator says Amazon quietly raised ad prices for businesses - here's what it means for sellers and Amazon's ad empire.
New machine learning tools give ornithologists real-time visibility into ancient journeys - and signal a broader shift toward AI-driven environmental monitoring.
A 64-year-old earns more on her own record but faces a timing trade-off between spousal and personal benefits that could cost her tens of thousands.
Apple's CEO is preparing to hand over the reins, and the stock dip shows how much investors value continuity.
The legacy app's political stand turned a naming dispute into a user-driven surge, reshaping competitive dynamics in navigation.
A hidden developer option on Android can tame erratic Bluetooth audio levels. Here's how to find it and why it works.
Researchers studying AI consciousness are getting unsolicited emails from the bots themselves, forcing a new kind of conversation.
Citigroup projects a $12 trillion market cap for SpaceX, but banks' lofty price targets ignore the company's struggle to reach public-market exit velocity. Here's what the research really says.